Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug duo aims to stop stroke damage in its tracks

NCT ID NCT06696820

First seen Mar 10, 2026 · Last updated May 23, 2026 · Updated 10 times

Summary

This study tests whether giving a powerful cholesterol-lowering drug (evolocumab) along with standard statins within 48 hours of a stroke can prevent early brain function decline. About 429 adults with moderate-to-severe artery narrowing in the brain will be randomly assigned to receive either the combo or statins alone. The goal is to see if the combo reduces early worsening and improves recovery at 90 days, while monitoring for bleeding risks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Tongji Hospital,Tongji Medical College, Huazhong University of Science and Technology

    NOT_YET_RECRUITING

    Wuhan, Hubei, 430030, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.